AU2011301847B2 - Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure - Google Patents

Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure Download PDF

Info

Publication number
AU2011301847B2
AU2011301847B2 AU2011301847A AU2011301847A AU2011301847B2 AU 2011301847 B2 AU2011301847 B2 AU 2011301847B2 AU 2011301847 A AU2011301847 A AU 2011301847A AU 2011301847 A AU2011301847 A AU 2011301847A AU 2011301847 B2 AU2011301847 B2 AU 2011301847B2
Authority
AU
Australia
Prior art keywords
alkyl
methyl
ethyl
imidazol
benzyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011301847A
Other languages
English (en)
Other versions
AU2011301847A1 (en
Inventor
Ken Chow
Mohammed I. Dibas
John E. Donello
Michael E. Garst
Daniel W. Gil
Liming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011301847(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2011301847A1 publication Critical patent/AU2011301847A1/en
Application granted granted Critical
Publication of AU2011301847B2 publication Critical patent/AU2011301847B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011301847A 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure Active AU2011301847B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US61/383,370 2010-09-16
PCT/US2011/051990 WO2012037490A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
AU2011301847A1 AU2011301847A1 (en) 2013-05-02
AU2011301847B2 true AU2011301847B2 (en) 2016-02-11

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2011301847A Active AU2011301847B2 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
AU2011301856A Active AU2011301856C1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
AU2011301901A Active AU2011301901B2 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
AU2011301932A Active AU2011301932C1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2011301856A Active AU2011301856C1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
AU2011301901A Active AU2011301901B2 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
AU2011301932A Active AU2011301932C1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Country Status (28)

Country Link
US (9) US8492557B2 (enExample)
EP (13) EP2616066B1 (enExample)
JP (4) JP6045495B2 (enExample)
KR (7) KR101840501B1 (enExample)
CN (5) CN105412092B (enExample)
AR (4) AR083019A1 (enExample)
AU (4) AU2011301847B2 (enExample)
BR (4) BR112013006352A2 (enExample)
CA (8) CA2811559A1 (enExample)
CL (4) CL2013000736A1 (enExample)
CY (3) CY1121024T1 (enExample)
DK (9) DK3050563T3 (enExample)
ES (10) ES2687420T3 (enExample)
HU (5) HUE048725T2 (enExample)
IL (4) IL225281A0 (enExample)
MX (4) MX2013003009A (enExample)
MY (4) MY168763A (enExample)
NZ (1) NZ608751A (enExample)
PL (7) PL3050563T3 (enExample)
PT (7) PT3050564T (enExample)
RU (4) RU2013116763A (enExample)
SG (4) SG188573A1 (enExample)
SI (5) SI3050564T1 (enExample)
TR (1) TR201909249T4 (enExample)
TW (4) TW201240661A (enExample)
UA (1) UA112973C2 (enExample)
WO (4) WO2012037453A1 (enExample)
ZA (4) ZA201302194B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093930A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN111386275B (zh) * 2018-08-24 2023-03-10 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
CA3214876A1 (en) * 2021-04-16 2022-10-20 Wenkui Ken Fang Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
EP4661868A1 (en) * 2023-02-08 2025-12-17 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034998A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2009089132A1 (en) * 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ES2188649T3 (es) 1993-11-15 2003-07-01 Schering Corp Fenil-alquil-imidazoles como antagonistas del receptor h3.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
WO2005006720A1 (en) * 2003-07-14 2005-01-20 Koninklijke Philips Electronics N.V. Projection device
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
AU2010210513A1 (en) 2009-02-06 2011-09-01 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034998A2 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2009089132A1 (en) * 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENTILI et al. Current Topics in Medicinal Chemistry (2007), vol. 7, no. 2, pages 163-168 *

Also Published As

Publication number Publication date
RU2013116403A (ru) 2014-10-27
SG188571A1 (en) 2013-04-30
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
TWI591058B (zh) 2017-07-11
ES2904479T3 (es) 2022-04-05
JP2013541527A (ja) 2013-11-14
EP3078376A1 (en) 2016-10-12
TW201305117A (zh) 2013-02-01
KR20130114140A (ko) 2013-10-16
JP2013540749A (ja) 2013-11-07
ZA201302288B (en) 2013-11-27
KR101840501B1 (ko) 2018-05-04
EP3050564B1 (en) 2019-09-04
AU2011301901B2 (en) 2016-02-11
HUE048725T2 (hu) 2020-09-28
EP3050563B1 (en) 2018-05-09
AU2011301932C1 (en) 2016-09-01
CA2812191C (en) 2021-04-13
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
CA2812197C (en) 2024-01-02
AR083020A1 (es) 2013-01-23
CL2013000735A1 (es) 2013-11-29
PL2616068T3 (pl) 2016-11-30
TW201240661A (en) 2012-10-16
TW201240662A (en) 2012-10-16
PT3050563T (pt) 2018-10-01
RU2013116541A (ru) 2014-10-27
SG188573A1 (en) 2013-04-30
EP2616069B1 (en) 2016-11-16
US8492422B2 (en) 2013-07-23
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21
CA2812195A1 (en) 2012-03-22
AU2011301847A1 (en) 2013-05-02
TW201305116A (zh) 2013-02-01
CN103200942A (zh) 2013-07-10
PL3348264T3 (pl) 2020-08-24
US20120122945A1 (en) 2012-05-17
KR101952457B1 (ko) 2019-02-26
EP2616067B1 (en) 2016-05-18
IL225278A0 (en) 2013-06-27
EP3050564A1 (en) 2016-08-03
SI3050564T1 (sl) 2020-02-28
SG188572A1 (en) 2013-04-30
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
HK1257416A1 (en) 2019-10-18
WO2012037453A1 (en) 2012-03-22
EP2616068A1 (en) 2013-07-24
ES2760920T3 (es) 2020-05-18
HUE039090T2 (hu) 2018-12-28
MY191369A (en) 2022-06-20
US20150148394A1 (en) 2015-05-28
MX2013003004A (es) 2013-06-28
EP3078376B1 (en) 2019-03-27
WO2012037484A1 (en) 2012-03-22
MY161607A (en) 2017-04-28
EP2616066A1 (en) 2013-07-24
MX2013003002A (es) 2013-06-28
KR102354097B1 (ko) 2022-01-20
AU2011301901A1 (en) 2013-05-02
JP6073229B2 (ja) 2017-02-01
EP2616066B1 (en) 2016-07-13
AU2011301932B2 (en) 2016-02-25
KR102104760B1 (ko) 2020-04-27
AU2011301856C1 (en) 2016-09-08
CL2013000736A1 (es) 2013-07-12
SI3338777T1 (sl) 2020-08-31
HUE038698T2 (hu) 2018-11-28
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
BR112013006352A2 (pt) 2016-06-28
EP3636263B1 (en) 2021-11-03
EP3053576A1 (en) 2016-08-10
CA3122745A1 (en) 2012-03-22
HUE049573T2 (hu) 2020-10-28
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
US20120149746A1 (en) 2012-06-14
PT2616068T (pt) 2016-09-13
SI3053576T1 (sl) 2018-11-30
WO2012037499A1 (en) 2012-03-22
EP3050563A1 (en) 2016-08-03
PL3338777T3 (pl) 2020-07-13
CA3116249A1 (en) 2012-03-22
ES2781681T3 (es) 2020-09-04
AR083018A1 (es) 2013-01-23
HK1185538A1 (zh) 2014-02-21
UA112973C2 (uk) 2016-11-25
EP3053576B1 (en) 2018-05-16
KR20200091507A (ko) 2020-07-30
US20130289088A1 (en) 2013-10-31
KR20190022895A (ko) 2019-03-06
MY173846A (en) 2020-02-24
DK3348264T3 (da) 2020-03-23
KR20140003407A (ko) 2014-01-09
NZ608751A (en) 2015-04-24
US20160354346A1 (en) 2016-12-08
CN105412092A (zh) 2016-03-23
BR112013006320A2 (pt) 2016-06-21
MX2013003009A (es) 2013-06-28
BR112013006355A2 (pt) 2016-06-28
AR083019A1 (es) 2013-01-23
SG188570A1 (en) 2013-04-30
IL225280A0 (en) 2013-06-27
CY1121024T1 (el) 2019-12-11
ES2788051T3 (es) 2020-10-20
US8492557B2 (en) 2013-07-23
TR201909249T4 (tr) 2019-07-22
EP3348264B1 (en) 2020-01-01
US8501796B2 (en) 2013-08-06
CN105412092B (zh) 2020-11-17
DK2616069T3 (en) 2016-12-19
RU2013116405A (ru) 2014-10-27
ES2737230T3 (es) 2020-01-10
DK3050563T3 (en) 2018-08-13
PT3348264T (pt) 2020-04-02
DK3636263T3 (da) 2022-01-10
PT3338777T (pt) 2020-05-06
CA3077732A1 (en) 2012-03-22
CA2812191A1 (en) 2012-03-22
DK3338777T3 (da) 2020-04-20
PT2616069T (pt) 2016-12-06
MX2013003008A (es) 2013-06-28
WO2012037490A1 (en) 2012-03-22
US20130296394A1 (en) 2013-11-07
IL225282A0 (en) 2013-06-27
HK1185541A1 (zh) 2014-02-21
US20120142746A1 (en) 2012-06-07
ES2607084T3 (es) 2017-03-29
DK3078376T3 (da) 2019-06-24
CY1122958T1 (el) 2021-10-29
KR102139905B1 (ko) 2020-07-31
MY168763A (en) 2018-12-04
PL3050563T3 (pl) 2018-12-31
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
CA2812197A1 (en) 2012-03-22
PL3053576T3 (pl) 2018-11-30
PT3053576T (pt) 2018-10-08
EP3348264A1 (en) 2018-07-18
KR101840500B1 (ko) 2018-03-20
HK1185539A1 (zh) 2014-02-21
PL2616069T3 (pl) 2017-04-28
JP2013537236A (ja) 2013-09-30
US20120136036A1 (en) 2012-05-31
CA2811559A1 (en) 2012-03-22
EP3636263A1 (en) 2020-04-15
ES2687420T3 (es) 2018-10-25
CY1122809T1 (el) 2021-05-05
PT3050564T (pt) 2019-12-11
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
EP2616067A1 (en) 2013-07-24
EP3659600A1 (en) 2020-06-03
CN103209694A (zh) 2013-07-17
EP3338777A1 (en) 2018-06-27
JP6045495B2 (ja) 2016-12-14
CA3079450A1 (en) 2012-03-22
RU2612351C2 (ru) 2017-03-07
DK3053576T3 (en) 2018-08-20
CN103200941A (zh) 2013-07-10
US8853251B2 (en) 2014-10-07
CL2013000733A1 (es) 2013-08-23
US8653123B2 (en) 2014-02-18
AU2011301856A1 (en) 2013-05-02
CN103200941B (zh) 2015-12-16
DK3050564T3 (da) 2019-11-25
DK2616068T3 (en) 2016-08-29
KR20200044147A (ko) 2020-04-28
ES2684055T3 (es) 2018-10-01
HUE047476T2 (hu) 2020-04-28
US20140057958A1 (en) 2014-02-27
SI3050563T1 (sl) 2018-10-30
EP3698789A1 (en) 2020-08-26
CL2013000734A1 (es) 2013-11-08
ES2593612T3 (es) 2016-12-12
SI3348264T1 (sl) 2020-07-31
PL3050564T3 (pl) 2020-06-01
ZA201302194B (en) 2013-11-27
ZA201302193B (en) 2013-11-27
BR112013006320B1 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
AU2011301847B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
AU2011301856B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
HK40036790A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
HK40028884A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK40028884B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2- methylphenyl] methanol
HK1185541B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for lowering intraocular pressure
HK1185539B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)